Deal-Making

Takeda loans J&J CDMO space to support COVID vaccine roll out

IDT Biologika will use capacity reserved for Takeda’s dengue vaccine candidate to provide fill-finish for Johnson & Johnson’s COVID-19 single-shot jab. Contract development manufacturing organization (CDMO) IDT Biologika had been contracted to use its Dessau site in Germany to manufacture Takeda’s dengue vaccine candidate, TAK-003. However, the facility will now be dedicated to filling and packaging J&J’s vaccine, which received US Food and Drug Administration (FDA) approval in February this year. J&J’s vaccine will be manufactured at the Dessau site…

Lonza dedicates suite to make Altimmune’s nasal COVID-19 vaccine

Lonza will commission a dedicated suite at its Houston, US facility for supply of Altimmune’s AdCOVID, a nasal COVID-19 vaccine that entered Phase I trials last month. Last November, Altimmune entered an agreement which meant that Lonza would provide commercial production capacity for AdCOVID from its Houston, US, site. Now, Altimmune has expanded its manufacturing partnership with lonza by adding capacity and stability through its own dedicated suite. “Our recently inaugurated Houston facility is our center of excellence for process…

Ins & Outs: Ex-Lonza CEO joins Recipharm, plus changes at Moderna

Marc Funk has joined CDMO Recipharm as its new CEO, while Moderna pinches Novartis’s chief legal officer. Meanwhile, there are high level changes at Univercells Technologies. It’s lovely to have you here for another BioProcess Insider’s, Ins & Outs. This week, Marc Funk announced on LinkedIn  that he has joined Recipharm as CEO. Funk has replaced contract development manufacturing organization (CDMO) Recipharm’s former CEO, Thomas Eldered who had held this position since 2008. “It is a great pleasure to be…

Pfizer exits Chinese biosimilars space, selling plant to WuXi

As part of a “difficult decision” to halt its biosimilars programs in China, Pfizer is offloading its single-use biologics manufacturing plant in Hangzhou to WuXi Biologics. Pfizer is one of the world’s largest biosimilar manufacturers, with seven commercialized products in the US alone (Inflectra, Retacrit, Nivestym, Nyvepria, Zirabev, Trazimera, Ruxience). In 2016, Pfizer took aim at the Chinese market by investing $350 million in the Hangzhou Economic Development Area (HEDA) to set up a biosimilars manufacturing facility. Five years on…

Industry hot for cold chain technologies, says thermal packaging firm

Cold Chain Technologies has scaled-up capacity after seeing an unprecedented demand for its services during the coronavirus pandemic. The thermal packaging solutions company, Cold Chain Technologies is part of the US government’s Operation Warp Speed (OWS) vaccine distribution plan and director of Corporate Development, Jamie Chasteen told BioProcess Insider it has seen a “huge bump” in demand since COVID-19. To meet this demand, the firm opened a manufacturing plant in less than eight weeks in Lebanon, Tennessee in November 2020…

ConserV Bioscience and eTheRNA to develop HIV vaccine

ConserV Bioscience and eTheRNA will share their expertise to develop an mRNA-based vaccine for HIV. The partnership will bring together ConserV’s services in identifying protective antigens and eTheRNA’s TriMix immunostimulatory mRNA technology and novel lipid nanoparticle encapsulation technologies. “We will first collaborate on an mRNA vaccine against HIV,” Tim Van Assche, director of Business Development and Alliance Management at eTheRNA Immunotherapies told BioProcess Insider. “In case results are positive, the collaboration will be extended to other mRNA vaccine formulations based…

Univercells Technologies teams with High Purity New England for distribution

High Purity New England (HPNE) will market and sell Univercells Technologies’ products in the US after the two firms enter an agreement. No financials are connected to the agreement, however HPNE is now an authorized distributor of the firm’s technology offerings, which includes the Nevoline Upstream platform, the scale-X carbo system, and the scale-X hydro system. “The goal is to increase reach, expand the sales pipeline and further build the supply and service organization, recognizing the importance of being closer…

Novartis: Kundl shines bright for CureVac’s COVID vaccine

Novartis has invested €20 million ($23.8m) to service the CureVac deal and says up to 100 jobs will be created at its Kundl site in Austria.   Last week, Novartis became the latest firm to partner with CureVac to help manufacture its COVID-19 candidate, CVnCoV, at Novartis’ site in Kundl, Austria. The firm plans to manufacture up to 50 million doses by the end of 2021 and, potentially, a further 200 million doses by 2022. A spokesperson for Novartis told…

Exelixis inks deal with WuXi Bio as it advances ADC ambition

“We really like the ADC space,” says Exelixis as it licenses a panel of monoclonal antibodies from WuXi Biologics. Californian pharma firm Exelixis has paid what it describes as a “modest” upfront payment to Chinese drugmaker WuXi Biologics for the exclusive license of a panel of monoclonal antibodies to a preclinically validated target for the development of antibody-drug conjugates (ADCs), bispecifics, and other biologic applications. “Our agreement with WuXi Bio enhances our growing biotherapeutics portfolio by providing an approach to…

Novartis inks COVID-19 vaccine deal with CureVac

Novartis is the latest firm to partner with CureVac and plans to help make up to 250 million doses of its COVID-19 vaccine candidate, CVnCoV by 2022.  The Swiss firm is set to support manufacturing of CVnCoV, an mRNA-based COVID-19 vaccine candidate, which is currently in Phase II studies and expected to merge into a Phase III efficacy trial. The manufacturing is anticipated to start in Q2, 2021 at Novartis’ site in Kundl, Austria. The firm is aiming to produce…